EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial resistance in northern Australia: the HOTspots surveillance and response program annual epidemiology report 2022

Teresa M Wozniak, Alys R Young, Aminath Shausan, Amy Legg, Michael J Leung, Sonali A Coulter, Shalinie Pereira, Robert W Baird, Majella G Murphy

Communicable Diseases Intelligence · 2025

DOI: 10.33321/cdi.2025.49.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Teresa M Wozniak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Australian e-Health Research Centre, Commonwealth Scientific and Industrial and Research Organisation, STARS Herston, Queensland, 4029, Australia. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Anti-Bacterial Agents, Escherichia coli, Drug Resistance, Bacterial. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The HOTspots surveillance and response program monitors antimicrobial resistance (AMR) in selected bacterial pathogens across three jurisdictions in northern Australia. In 2022, the program collected data from 164 community healthcare clinics and 50 hospitals to assess AMR trends and geographic variations.

Methods

Data on resistance rates for methicillin-resistant Staphylococcus aureus (MRSA) and for Escherichia coli (E. coli) were analysed. Geographic regions were compared to identify variations in AMR across the Northern Territory, northern Western Australia and northern Queensland. Resistance rates were compared between community clinics and hospitals.

Findings

In 2022, there were 56,003 clinical isolates submitted to HOTspots. Geographic variation was evident in S. aureus methicillin resistance, with MRSA accounting for 14.4% of S. aureus isolates in the east, 53.1% in central northern Australia and 46.3% in western northern Australia. Clindamycin-resistant MRSA was highest in the Northern Territory (21.7%) compared to Western Australia (16.1%) and Queensland (5.9%), limiting treatment options for community-acquired MRSA. Ceftriaxone-resistant E. coli also varied geographically, with resistance rates ranging from 3.9% in the east to 23.4% in central and 10.1% in the west. High rates of ceftriaxone resistance were observed in both community clinics (10.6%) and hospitals (16.3%). Nitrofurantoin-resistant E. coli remained low (0.2%) and stable over the past five years.

Interpretation

HOTspots data are critical for informing local antibiotic guidelines and aiding clinical decision-making. This detailed surveillance captures geographic and healthcare-setting-specific variations in AMR, which can improve regional treatment strategies across northern Australia, with a focus on the Northern Territory, which had previously lacked comprehensive surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsEscherichia coliDrug Resistance, BacterialEscherichia coli InfectionsHumansAustraliaEpidemiological MonitoringMicrobial Sensitivity TestsQueenslandStaphylococcal InfectionsNorthern Territory

Stichwörter der Autor:innen

antimicrobial resistancecommunitynorthern Australiaregionalsurveillance

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Australian e-Health Research Centre, Commonwealth Scientific and Industrial and Research Organisation, STARS Herston, Queensland, 4029, Australia.
  • Australian e-Health Research Centre, Commonwealth Scientific and Industrial and Research Organisation, Parkville, Melbourne, Victoria 3052, Australia.
  • Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
  • Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
  • Pathwest Pathology Medicine, Department of Health (WA Health), Perth, Western Australia, 6000, Australia.
  • Antimicrobial Stewardship Data, Pathology Queensland, Queensland Health, Herston, Queensland, 4029, Australia.

Zitieren

APA

Wozniak, T. M., Young, A. R., Shausan, A., Legg, A., Leung, M. J., Coulter, S. A., Pereira, S., Baird, R. W., & Murphy, M. G. (2025). Antimicrobial resistance in northern Australia: the HOTspots surveillance and response program annual epidemiology report 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.030

Vancouver

Wozniak TM, Young AR, Shausan A, Legg A, Leung MJ, Coulter SA, et al. Antimicrobial resistance in northern Australia: the HOTspots surveillance and response program annual epidemiology report 2022. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.030

BibTeX
@article{Wozniak2025,
  author = {Wozniak, Teresa M and Young, Alys R and Shausan, Aminath and Legg, Amy and Leung, Michael J and Coulter, Sonali A and Pereira, Shalinie and Baird, Robert W and Murphy, Majella G},
  title = {Antimicrobial resistance in northern Australia: the HOTspots surveillance and response program annual epidemiology report 2022},
  journal = {Communicable Diseases Intelligence},
  year = {2025},
  doi = {10.33321/cdi.2025.49.030}
}
Kostenlos starten →